Corneal axonal loss as an imaging biomarker of neurodegeneration in multiple sclerosis: a longitudinal study
IN Petropoulos, F Al-Shibani… - Therapeutic …, 2023 - journals.sagepub.com
Therapeutic Advances in Neurological Disorders, 2023•journals.sagepub.com
Background: Resourceful endpoints of axonal loss are needed to predict the course of
multiple sclerosis (MS). Corneal confocal microscopy (CCM) can detect axonal loss in
patients with clinically isolated syndrome and established MS, which relates to neurological
disability. Objective: To assess corneal axonal loss over time in relation to retinal atrophy,
and neurological and radiological abnormalities in MS. Methods: Patients with relapsing-
remitting (RRMS)(n= 68) or secondary progressive MS (SPMS)(n= 15) underwent CCM and …
multiple sclerosis (MS). Corneal confocal microscopy (CCM) can detect axonal loss in
patients with clinically isolated syndrome and established MS, which relates to neurological
disability. Objective: To assess corneal axonal loss over time in relation to retinal atrophy,
and neurological and radiological abnormalities in MS. Methods: Patients with relapsing-
remitting (RRMS)(n= 68) or secondary progressive MS (SPMS)(n= 15) underwent CCM and …
Background
Resourceful endpoints of axonal loss are needed to predict the course of multiple sclerosis (MS). Corneal confocal microscopy (CCM) can detect axonal loss in patients with clinically isolated syndrome and established MS, which relates to neurological disability.
Objective
To assess corneal axonal loss over time in relation to retinal atrophy, and neurological and radiological abnormalities in MS.
Methods
Patients with relapsing-remitting (RRMS) (n = 68) or secondary progressive MS (SPMS) (n = 15) underwent CCM and optical coherence tomography. Corneal nerve fibre density (CNFD-fibres/mm2), corneal nerve branch density (CNBD-branches/mm2), corneal nerve fibre length (CNFL-mm/mm2) and retinal nerve fibre layer (RNFL-μm) thickness were quantified along with neurological and radiological assessments at baseline and after 2 years of follow-up. Age-matched, healthy controls (n = 20) were also assessed.
Results
In patients with RRMS compared with controls at baseline, CNFD (p = 0.004) and RNFL thickness (p < 0.001) were lower, and CNBD (p = 0.003) was higher. In patients with SPMS compared with controls, CNFD (p < 0.001), CNFL (p = 0.04) and RNFL thickness (p < 0.001) were lower. For identifying RRMS, CNBD had the highest area under the receiver operating characteristic (AUROC) curve (0.99); and for SPMS, CNFD had the highest AUROC (0.95). At follow-up, there was a further significant decrease in CNFD (p = 0.04), CNBD (p = 0.001), CNFL (p = 0.008) and RNFL (p = 0.002) in RRMS; in CNFD (p = 0.04) and CNBD (p = 0.002) in SPMS; and in CNBD (p = 0.01) in SPMS compared with RRMS. Follow-up corneal nerve loss was greater in patients with new enhancing lesions and optic neuritis history.
Conclusion
Progressive corneal and retinal axonal loss was identified in patients with MS, especially those with more active disease. CCM may serve as an imaging biomarker of axonal loss in MS.
Sage Journals
以上显示的是最相近的搜索结果。 查看全部搜索结果